The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
allyl sulfide inhibits the reaction [Pyrazines results in increased activity of CYP2E1 protein]; allyl sulfide inhibits the reaction [Pyrazines results in increased expression of CYP2E1 protein]
Pyrazines inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 mRNA] which results in increased chemical synthesis of Nitric Oxide]; Pyrazines inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]
5-(N,N-hexamethylene)amiloride results in increased cleavage of and results in increased activity of and affects the localization of SERPINB1 protein modified form
Amiloride inhibits the reaction [AGT protein results in increased expression of ATP1A1 mRNA] Amiloride results in increased expression of AGT protein modified form
Amiloride results in decreased phosphorylation of and results in decreased activity of AKT1 protein; Okadaic Acid inhibits the reaction [Amiloride results in decreased phosphorylation of AKT1 protein]
Amiloride binds to AOC1 protein Amiloride inhibits the reaction [Phenylamil binds to Aoc1 protein] Amiloride binds to Aoc1 protein Amiloride inhibits the reaction [AOC1 protein results in increased degradation of Putrescine] Amiloride results in decreased activity of AOC1 protein
Amiloride promotes the reaction [TNFSF10 protein results in increased activity of CASP3 protein]; Amiloride promotes the reaction [TNFSF10 protein results in increased cleavage of and results in increased activity of CASP3 protein] Amiloride inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]
Amiloride promotes the reaction [TNFSF10 protein results in increased activity of CASP8 protein]; Amiloride promotes the reaction [TNFSF10 protein results in increased cleavage of and results in increased activity of CASP8 protein]
Amiloride inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CCL2 protein] Amiloride results in decreased expression of CCL2 mRNA; Amiloride results in decreased expression of CCL2 protein Amiloride inhibits the reaction [ALB protein results in increased expression of CCL2 protein]; Amiloride inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; Amiloride inhibits the reaction [Ouabain results in increased expression of CCL2 protein]; Sodium deficiency inhibits the reaction [Amiloride results in decreased expression of CCL2 mRNA]; Sodium deficiency inhibits the reaction [Amiloride results in decreased expression of CCL2 protein]
Amiloride results in increased expression of FOS mRNA Amiloride inhibits the reaction [Acids results in increased expression of and results in increased localization of FOS protein]
Amiloride inhibits the reaction [Tunicamycin results in increased expression of HSPA5 mRNA]; Amiloride inhibits the reaction [Tunicamycin results in increased expression of HSPA5 protein]
Amiloride inhibits the reaction [IFNG protein results in increased expression of PLAUR mRNA] Amiloride inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with IFNG protein] results in increased secretion of IL12B protein]
Amiloride inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; Amiloride inhibits the reaction [IL1B protein results in increased expression of CXCL8 mRNA]; Amiloride inhibits the reaction [IL1B protein results in increased expression of SELE protein]; Amiloride inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK1 protein]; Amiloride inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK3 protein]; Amiloride inhibits the reaction [IL1B protein results in increased secretion of CXCL8 protein]
Amiloride inhibits the reaction [TNF protein results in increased expression of ITGAL mRNA]; Amiloride inhibits the reaction [TNF protein results in increased expression of ITGAL protein]
KLK1 protein affects the susceptibility to [Amiloride results in increased secretion of Sodium] KLK1 protein results in increased susceptibility to Amiloride
Amiloride inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; Amiloride inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of and results in increased activity of NFKB1 protein]
Amiloride inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased degradation of and results in decreased expression of NFKBIA protein]
Amiloride promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]; Okadaic Acid inhibits the reaction [Amiloride promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]
Amiloride results in decreased activity of [PKD2 protein binds to PKD2 protein]; Amiloride results in decreased activity of [PKD2 protein binds to TRPC1 protein]
Amiloride inhibits the reaction [IFNA2 protein results in increased expression of PLAUR mRNA]; Amiloride inhibits the reaction [IFNG protein results in increased expression of PLAUR mRNA]
Amiloride results in decreased phosphorylation of PPP1CA protein Okadaic Acid inhibits the reaction [Amiloride results in decreased phosphorylation of PPP1CA protein]
Amiloride inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein] Amiloride inhibits the reaction [Doxorubicin results in increased expression of PTGS2 protein]
Amiloride inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; Amiloride inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of and results in increased activity of RELA protein] Amiloride inhibits the reaction [Doxorubicin results in increased expression of RELA protein]
Amiloride inhibits the reaction [[SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein] which results in increased transport of Sodium]; Amiloride results in decreased activity of [SCNN1A binds to SCNN1B binds to SCNN1G binds to SCNN1D]; Amiloride results in decreased activity of [SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein] [farglitazar co-treated with Amiloride] results in increased expression of SCNN1A mRNA Amiloride affects the activity of SCNN1A protein
Amiloride inhibits the reaction [[SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein] which results in increased transport of Sodium]; Amiloride results in decreased activity of [SCNN1A binds to SCNN1B binds to SCNN1G binds to SCNN1D]; Amiloride results in decreased activity of [SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein] Amiloride affects the activity of SCNN1B protein
Amiloride affects the activity of SCNN1G protein Amiloride inhibits the reaction [[SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein] which results in increased transport of Sodium]; Amiloride results in decreased activity of [SCNN1A binds to SCNN1B binds to SCNN1G binds to SCNN1D]; Amiloride results in decreased activity of [SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein]
Amiloride results in decreased activity of SLC47A1 protein Amiloride inhibits the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]
[Amiloride results in decreased activity of SLC9A2 protein] which results in decreased transport of Chlorides; [Amiloride results in decreased activity of SLC9A2 protein] which results in decreased transport of Sodium
Amiloride inhibits the reaction [TNF protein results in increased expression of ITGAL mRNA]; Amiloride inhibits the reaction [TNF protein results in increased expression of ITGAL protein]; Lipopolysaccharides inhibits the reaction [Amiloride results in increased expression of TNF] Amiloride inhibits the reaction [Doxorubicin results in increased expression of TNF protein]
Amiloride promotes the reaction [TNFSF10 protein affects the localization of CYCS protein]; Amiloride promotes the reaction [TNFSF10 protein results in increased activity of CASP3 protein]; Amiloride promotes the reaction [TNFSF10 protein results in increased activity of CASP8 protein]; Amiloride promotes the reaction [TNFSF10 protein results in increased cleavage of and results in increased activity of CASP3 protein]; Amiloride promotes the reaction [TNFSF10 protein results in increased cleavage of and results in increased activity of CASP8 protein]; Amiloride promotes the reaction [TNFSF10 protein results in increased cleavage of and results in increased activity of CASP9 protein]; Amiloride promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]; Okadaic Acid inhibits the reaction [Amiloride promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [resiniferatoxin inhibits the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]]; 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester promotes the reaction [resiniferatoxin promotes the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]]; [Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein; Calcium Chloride inhibits the reaction [resiniferatoxin affects the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]]; Ionomycin promotes the reaction [Calcium Chloride inhibits the reaction [resiniferatoxin affects the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]]]; resiniferatoxin inhibits the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]; resiniferatoxin promotes the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein] [Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein; Cyclosporine affects the reaction [resiniferatoxin affects the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]]; Ionomycin inhibits the reaction [resiniferatoxin affects the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]]; N-(3-methoxyphenyl)-4-chlorocinnamanilide inhibits the reaction [resiniferatoxin affects the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]]; resiniferatoxin affects the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]; Tacrolimus affects the reaction [resiniferatoxin affects the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]]; Tetradecanoylphorbol Acetate affects the reaction [resiniferatoxin affects the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]]
[Bortezomib co-treated with Doxorubicin] results in decreased expression of ABCB1 protein; ATP2A1 protein affects the reaction [Bortezomib results in decreased expression of ABCB1]; Bortezomib inhibits the reaction [CERS2 protein affects the expression of ABCB1 protein]; Bortezomib inhibits the reaction [CERS6 protein affects the expression of ABCB1 protein]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of ABCB1 mRNA]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of and results in increased nitrosation of ABCB1 protein]; Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1 protein; Chloroquine promotes the reaction [Bortezomib results in decreased expression of ABCB1 mRNA]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1 protein] [Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein; Bortezomib promotes the reaction [Chloroquine results in decreased expression of ABCB1A mRNA]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of and results in increased nitrosation of ABCB1A protein]; Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1A protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of ABCB1A mRNA]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1A protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]] Bortezomib results in decreased expression of ABCB1; Bortezomib results in decreased expression of ABCB1 mRNA; Bortezomib results in decreased expression of ABCB1 protein Bortezomib results in decreased activity of ABCB1 protein
[alvocidib co-treated with Bortezomib co-treated with ABL1 protein] results in decreased phosphorylation of LYN protein; [alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein; [alvocidib co-treated with Bortezomib] results in decreased expression of ABL1 protein; [Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of ABL1 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in decreased expression of ABL1 protein; Bortezomib promotes the reaction [Dichlororibofuranosylbenzimidazole results in decreased expression of ABL1 protein]
Bortezomib affects the localization of AIFM1 protein [Bortezomib co-treated with Butyrates] affects the localization of AIFM1 protein; [Bortezomib co-treated with vorinostat] affects the localization of AIFM1 protein
[alvocidib co-treated with Bortezomib] results in decreased expression of AKT1 protein modified form; [Bortezomib co-treated with lapatinib] results in decreased phosphorylation of AKT1 protein; [Bortezomib co-treated with lonafarnib] results in decreased expression of AKT1 protein; [Bortezomib co-treated with lonafarnib] results in decreased expression of AKT1 protein modified form; [Bortezomib co-treated with panobinostat] results in decreased activity of AKT1 protein; [Bortezomib co-treated with sorafenib] results in decreased phosphorylation of AKT1 protein; [Bortezomib results in decreased activity of CBL protein] promotes the reaction [arsenic trioxide results in increased activity of AKT1 protein]; [geldanamycin co-treated with Bortezomib] results in decreased expression of AKT1 protein; [vorinostat co-treated with Bortezomib] results in decreased phosphorylation of and results in decreased expression of AKT1 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP3 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP9 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of PARP1 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein]; AKT1 protein results in decreased susceptibility to [Bortezomib co-treated with sorafenib]; Bortezomib inhibits the reaction [TNFSF10 protein results in increased activity of AKT1 protein]; Okadaic Acid inhibits the reaction [Bortezomib results in decreased expression of AKT1 protein modified form] Bortezomib results in decreased activity of AKT1 protein
Bortezomib binds to and results in decreased activity of AR protein; Bortezomib inhibits the reaction [Metribolone results in increased activity of AR protein]
pyrazolanthrone inhibits the reaction [Bortezomib results in increased phosphorylation of ATF2 protein] Bortezomib results in increased expression of ATF2 mRNA
ATF3 results in increased susceptibility to Bortezomib Bortezomib results in increased expression of ATF3 mRNA; Bortezomib results in increased expression of ATF3 protein Bortezomib results in increased expression of ATF3; Bortezomib results in increased expression of ATF3 mRNA; Bortezomib results in increased expression of ATF3 protein [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ATF3 mRNA; ATF3 mutant form promotes the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased expression of ATF4 protein]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 protein]; Bortezomib promotes the reaction [ATF4 protein binds to PMAIP1 promoter]; Dactinomycin inhibits the reaction [Bortezomib results in increased expression of ATF4 mRNA]; Dactinomycin inhibits the reaction [Bortezomib results in increased expression of ATF4 protein]; NUPR1 mutant form promotes the reaction [Bortezomib results in increased expression of ATF4 mRNA] Bortezomib results in increased expression of ATF4 mRNA; Bortezomib results in increased expression of ATF4 protein ATF4 results in decreased susceptibility to Bortezomib
ATG5 gene mutant form inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]]
[CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of ATM protein]
[nutlin 3 co-treated with Bortezomib] results in increased activity of BAK1 protein; BAK1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] BAK1 protein results in increased susceptibility to [Bortezomib co-treated with TNFSF10 protein] Bortezomib results in increased expression of BAK1 protein
[Bortezomib co-treated with arsenic trioxide] affects the expression of BAX protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of BAX protein; BAX results in increased susceptibility to [Bortezomib co-treated with panobinostat]; Bortezomib inhibits the reaction [BAX mutant form inhibits the reaction [TNFSF10 protein results in increased localization of DIABLO protein]] Bortezomib results in increased expression of BAX protein
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of BCL2 mRNA; [Bortezomib co-treated with arsenic trioxide] affects the expression of BCL2 protein; [Bortezomib co-treated with arsenic trioxide] results in decreased expression of BCL2 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of BCL2 protein; [Bortezomib co-treated with Daunorubicin] results in decreased expression of BCL2 mRNA; [Bortezomib co-treated with vorinostat] results in increased cleavage of BCL2 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of BCL2 protein; [vorinostat co-treated with Bortezomib] results in decreased expression of BCL2 protein; BCL2 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2 protein modified form] Bortezomib results in increased expression of BCL2 mRNA; Bortezomib results in increased expression of BCL2 protein Bortezomib results in decreased expression of BCL2 mRNA; Bortezomib results in decreased expression of BCL2 protein
[romidepsin co-treated with Bortezomib] results in decreased expression of BCL2A1 protein Bortezomib results in increased expression of BCL2A1A protein
[alvocidib co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [romidepsin co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [Vorinostat co-treated with Bortezomib] results in decreased expression of BCL2L1 protein alternative form; [Vorinostat co-treated with Bortezomib] results in increased expression of BCL2L1 mRNA alternative form; [Vorinostat co-treated with Bortezomib] results in increased expression of BCL2L1 protein alternative form; BCL2L1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; BCL2L1 protein results in decreased susceptibility to [Bortezomib co-treated with trichostatin A]; Bortezomib promotes the reaction [capillarisin results in decreased expression of BCL2L1 protein]; lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2L1 protein]; SCIO-469 promotes the reaction [Bortezomib results in decreased expression of BCL2L1 protein]; trichostatin A promotes the reaction [Bortezomib results in decreased expression of BCL2L1 mRNA]; trichostatin A promotes the reaction [Bortezomib results in decreased expression of BCL2L1 protein] Bortezomib results in decreased expression of BCL2L1 mRNA; Bortezomib results in decreased expression of BCL2L1 protein Bortezomib results in increased expression of BCL2L1 protein BCL2L1 protein results in decreased susceptibility to Bortezomib
[Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein]; Bortezomib inhibits the reaction [Arsenic Trioxide results in increased degradation of BCL2L11 protein] Bortezomib results in increased expression of BCL2L11 protein Bortezomib results in increased activity of BCL2L11 protein BCL2L11 results in increased susceptibility to Bortezomib
BECN1 mutant form promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein] BECN1 protein results in decreased susceptibility to Bortezomib
Bortezomib results in increased cleavage of BID protein [Bortezomib co-treated with Butyrates] results in decreased expression of BID protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of BID protein; [Bortezomib co-treated with vorinostat] results in decreased expression of BID protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of BID protein; [TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of BID protein; [vorinostat co-treated with Bortezomib] results in increased cleavage of BID protein; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of BID protein]
BIK results in increased susceptibility to Bortezomib Bortezomib results in increased expression of BIK protein Bortezomib results in increased activity of BIK protein
Bortezomib results in decreased expression of BIRC2 protein [geldanamycin co-treated with Bortezomib] results in decreased expression of BIRC2 protein; [romidepsin co-treated with Bortezomib] results in decreased expression of BIRC2 protein
Bortezomib results in decreased expression of BIRC3 protein Bortezomib results in increased expression of BIRC3 mRNA; Bortezomib results in increased expression of BIRC3 protein [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of BIRC3 mRNA
Bortezomib results in decreased expression of BIRC5 mRNA; Bortezomib results in decreased expression of BIRC5 protein [Irinotecan co-treated with Bortezomib] results in decreased expression of BIRC5 protein; [romidepsin co-treated with Bortezomib] results in increased cleavage of BIRC5 protein; Bortezomib promotes the reaction [capillarisin results in decreased expression of BIRC5 protein] Bortezomib results in increased expression of BIRC5 protein
Bortezomib results in decreased expression of BRCA1 mRNA BRCA1 protein inhibits the reaction [BRCA1 gene mutant form results in increased susceptibility to Bortezomib] [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of AKR7A2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNF mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNG2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CRYGEP mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DAPK2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DLGAP5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of EGLN3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of FZD2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of H3C6 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of LGR4 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of RPS7P5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of THRA mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of TNFAIP8L1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of TNKS mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased activity of E2F1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ARID3B mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ATF3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of BIRC3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CCNB1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CRYAB mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CTH mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of DUSP5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ERN1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of FGF21 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GADD45A mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GDF15 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HECW1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HIKESHI mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of IL7R mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of KRTAP21-1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of MIR568 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PAWR mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PCYT1A mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of RND3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TNFAIP3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TNFRSF9 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TRIB3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TRIML2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ZNF613 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein]; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein] Bortezomib results in decreased ubiquitination of BRCA1 protein
[CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CALR mRNA]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; [Chloroquine co-treated with Bortezomib] promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; [Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein; [Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA; Bortezomib promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; Bortezomib results in increased expression of and affects the localization of CALR protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; DDIT3 protein affects the reaction [Bortezomib affects the localization of CALR protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; Doxorubicin promotes the reaction [Bortezomib affects the localization of CALR protein] [Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]]
benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein]; Bortezomib promotes the reaction [Brefeldin A results in increased cleavage of and results in increased activity of CASP2 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein; Brefeldin A promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein]; CASP2 protein affects the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein] CASP2 results in increased susceptibility to Bortezomib Bortezomib results in increased cleavage of CASP2 protein
Bortezomib results in increased activity of CASP3 protein Bortezomib results in increased cleavage of CASP3 protein 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; [Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein; [Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [SCIO-469 co-treated with Bortezomib] results in increased activity of CASP3 protein; ATG5 gene mutant form inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]]; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]]; HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein] 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; [Arsenic Trioxide co-treated with Bortezomib] results in increased activity of CASP3 protein; [Arsenic Trioxide co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP3 protein; [Bortezomib co-treated with abexinostat] results in increased activity of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] affects the expression of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP3 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with Doxorubicin] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with oblimersen co-treated with Cyclophosphamide] results in increased activity of CASP3 protein; [Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with Vorinostat] results in increased activity of CASP3 protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP3 protein; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of PRKDC protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; [Cisplatin co-treated with Bortezomib] results in increased activity of CASP3 protein; [Dexamethasone co-treated with Bortezomib] results in increased activity of CASP3 protein; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP3 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of CASP3 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased activity of CASP3 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [Vorinostat co-treated with Bortezomib] results in increased activity of CASP3 protein; [Vorinostat co-treated with Bortezomib] results in increased cleavage of CASP3 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein]; BECN1 mutant form promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[gambogic acid co-treated with Bortezomib] results in increased activity of CASP3 protein]; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [belinostat results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [capillarisin results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [gallium nitrate results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [NSC606985 results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [romidepsin results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [Thapsigargin results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [Tunicamycin results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [Vorinostat results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP3 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; DDIT3 protein affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; MAPK14 mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; ricolinostat promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; STK4 mutant form inhibits the reaction [Bortezomib results in increased activity of CASP3 protein]; TNFRSF10B mutant form inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased activity of CASP3 protein]; ZFAND2A protein inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein] Bortezomib results in increased expression of CASP3 protein
[Bortezomib co-treated with vorinostat] results in increased activity of CASP4 protein; CASP4 protein results in increased susceptibility to [Cisplatin co-treated with Bortezomib]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with vorinostat] results in increased activity of CASP4 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased cleavage of CASP4 protein] CASP4 protein results in increased susceptibility to Bortezomib Bortezomib results in increased activity of CASP4 protein
Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of CASP6 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP6 protein]
[Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP7 protein; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP7 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP7 protein; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP7 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP7 protein] Bortezomib results in increased activity of CASP7 protein
[Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of CASP8 mRNA; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP8 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP8 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib co-treated with Vorinostat] results in increased activity of CASP8 protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP8 protein; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of PRKDC protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP8 protein; [IFNA2 protein co-treated with Bortezomib] results in increased activity of CASP8 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [Vorinostat co-treated with Bortezomib] results in increased cleavage of CASP8 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [abexinostat results in increased cleavage of CASP8 protein]; Bortezomib promotes the reaction [Arsenic Trioxide results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of CASP8 protein]; Bortezomib promotes the reaction [Vorinostat results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP8 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP8 protein; CDKN1A protein affects the reaction [[TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein]; ricolinostat promotes the reaction [Bortezomib results in increased cleavage of CASP8 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP8 protein]; TNFRSF10B mutant form inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP8 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP8 protein]
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt affects the reaction [Bortezomib results in increased cleavage of CASP9 protein]; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP9 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP9 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP9 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP9 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib co-treated with Vorinostat] results in increased activity of CASP9 protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP9 protein; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP9 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP9 protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of CASP9 protein; [ricolinostat co-treated with Bortezomib] results in increased cleavage of CASP9 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP9 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP9 protein]; benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[gambogic acid co-treated with Bortezomib] results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [abexinostat results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Arsenic Trioxide results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [belinostat results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [romidepsin results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Vorinostat results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP9 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein; CASP2 protein affects the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP9 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased cleavage of CASP9 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP9 protein] Bortezomib results in increased expression of CASP9 protein CASP9 gene SNP results in increased susceptibility to Bortezomib; CASP9 results in increased susceptibility to Bortezomib
[Bortezomib results in increased expression of NFE2L2 protein] which results in increased expression of CBR3 mRNA; Bortezomib results in increased expression of CBR3 mRNA
Bortezomib results in increased expression of CCL3 mRNA; Bortezomib results in increased expression of CCL3 protein Bortezomib results in decreased expression of CCL3 mRNA
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CCNB1 protein; Bortezomib results in increased ubiquitination of and results in increased expression of CCNB1 protein Bortezomib results in increased expression of CCNB1 protein
[[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of CCND1 protein; [[Bortezomib co-treated with Vorinostat] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of CCND1 protein; [Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein; [Bortezomib co-treated with Vorinostat] results in decreased expression of CCND1 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of CCND1 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Vorinostat] results in decreased expression of CCND1 protein]; Bortezomib promotes the reaction [capillarisin results in decreased expression of CCND1 protein]
Bortezomib inhibits the reaction [docetaxel results in increased activity of CDK1 protein] Bortezomib results in increased phosphorylation of CDK1 protein Bortezomib results in increased activity of CDK1 protein Bortezomib results in decreased activity of CDK1 protein
Bortezomib results in increased stability of CDKN1A protein [Bortezomib co-treated with Butyrates] results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with Butyrates] results in increased expression of and results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with vorinostat] results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with vorinostat] results in increased expression of and results in increased cleavage of CDKN1A protein; [TNFSF10 protein co-treated with Bortezomib] results in increased expression of CDKN1A protein; [trichostatin A co-treated with Bortezomib] results in increased expression of CDKN1A mRNA; [trichostatin A co-treated with Bortezomib] results in increased expression of CDKN1A protein; [vorinostat co-treated with Bortezomib] results in increased expression of CDKN1A protein; Bortezomib promotes the reaction [abexinostat results in increased expression of CDKN1A protein]; CDKN1A protein affects the reaction [[TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein]; CDKN1A results in decreased susceptibility to [Bortezomib co-treated with docetaxel] CDKN1A results in decreased susceptibility to Bortezomib Bortezomib results in increased expression of CDKN1A mRNA; Bortezomib results in increased expression of CDKN1A protein
[Bortezomib co-treated with Butyrates] results in increased cleavage of CDKN1B protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of CDKN1B protein; [Vorinostat co-treated with Bortezomib] results in increased expression of CDKN1B protein; Bortezomib promotes the reaction [Lapatinib results in increased expression of CDKN1B protein]; Cisplatin promotes the reaction [Bortezomib results in increased expression of CDKN1B protein]; Lapatinib promotes the reaction [Bortezomib results in increased expression of CDKN1B protein] Bortezomib results in increased stability of CDKN1B protein
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CALR mRNA]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; [Chloroquine co-treated with Bortezomib] promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; [Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; Bortezomib inhibits the reaction [Arsenic Trioxide results in decreased expression of CEBPB mRNA]; Bortezomib promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of CEBPB protein alternative form] 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; [Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]] Bortezomib results in decreased expression of CEBPB mRNA
Bortezomib affects the expression of CFLAR protein [Bortezomib co-treated with TNFSF10 protein] results in decreased expression of CFLAR protein; [romidepsin co-treated with Bortezomib] results in decreased expression of CFLAR protein; TNFSF10 protein promotes the reaction [Bortezomib results in decreased expression of CFLAR protein] CFLAR protein alternative form results in decreased susceptibility to Bortezomib; CFLAR results in decreased susceptibility to Bortezomib Bortezomib results in decreased expression of CFLAR mRNA; Bortezomib results in decreased expression of CFLAR protein Bortezomib results in increased expression of CFLAR protein; Bortezomib results in increased expression of CFLAR protein alternative form; Bortezomib results in increased expression of CFLAR protein modified form
Bortezomib results in decreased expression of CREB1 protein Berberine inhibits the reaction [Bortezomib results in decreased expression of CREB1 protein]
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CRYAB mRNA Bortezomib results in increased expression of CRYAB mRNA
2-methoxyestradiol inhibits the reaction [CTNNB1 protein results in decreased susceptibility to Bortezomib]; arsenic trioxide inhibits the reaction [CTNNB1 protein results in decreased susceptibility to Bortezomib]; TNFSF10 protein inhibits the reaction [Bortezomib results in increased expression of CTNNB1 protein]
Bortezomib results in increased expression of CXCL2 mRNA Bortezomib results in increased expression of CXCL2 mRNA; Bortezomib results in increased expression of CXCL2 protein Bortezomib inhibits the reaction [Fluorouracil results in increased expression of CXCL2 mRNA]
[Bortezomib co-treated with Butyrates] affects the localization of CYCS protein; [Bortezomib co-treated with vorinostat] affects the localization of CYCS protein Bortezomib affects the localization of CYCS protein
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; [Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; Bortezomib inhibits the reaction [Tunicamycin results in increased expression of DDIT3 protein]; Bortezomib promotes the reaction [gambogic acid results in increased expression of DDIT3 protein]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; DDIT3 protein affects the reaction [Bortezomib affects the localization of CALR protein]; DDIT3 protein affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; gambogic acid promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased expression of DDIT3 protein] Bortezomib results in increased expression of DDIT3 mRNA; Bortezomib results in increased expression of DDIT3 protein 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; [Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein; [Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; Bortezomib inhibits the reaction [1,2-dithiol-3-thione inhibits the reaction [Tunicamycin results in increased expression of DDIT3 mRNA]]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]]; Nitroprusside inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Nitroprusside inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein] DDIT3 results in decreased susceptibility to Bortezomib
Bortezomib affects the localization of DIABLO protein Bortezomib results in increased localization of DIABLO protein Bortezomib results in increased expression of DIABLO mRNA; Bortezomib results in increased expression of DIABLO protein [alvocidib co-treated with Bortezomib] results in increased secretion of DIABLO protein; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in decreased localization of DIABLO protein; [Bortezomib co-treated with Butyrates] affects the localization of DIABLO protein; [Bortezomib co-treated with TNFSF10 protein] results in increased expression of DIABLO protein; [Bortezomib co-treated with vorinostat] affects the localization of DIABLO protein; Bortezomib inhibits the reaction [BAX mutant form inhibits the reaction [TNFSF10 protein results in increased localization of DIABLO protein]]; Bortezomib promotes the reaction [TNFSF10 protein results in increased localization of DIABLO protein]
Bortezomib results in decreased expression of EGR2 mRNA Bortezomib results in decreased expression of EGR2 mRNA; Bortezomib results in decreased expression of EGR2 protein
Bortezomib results in increased phosphorylation of EIF2AK3 protein Bortezomib inhibits the reaction [1,2-dithiol-3-thione inhibits the reaction [Tunicamycin results in increased expression of EIF2AK3 mRNA]] Bortezomib promotes the reaction [ricolinostat results in increased phosphorylation of EIF2AK3 protein]; EIF2AK3 mutant form inhibits the reaction [Bortezomib results in increased phosphorylation of EIF2S1 protein] EIF2AK3 results in decreased susceptibility to Bortezomib
Bortezomib affects the reaction [ricolinostat results in increased phosphorylation of EIF2S1 protein]; Bortezomib inhibits the reaction [Tunicamycin results in increased phosphorylation of EIF2S1 protein]; EIF2AK3 mutant form inhibits the reaction [Bortezomib results in increased phosphorylation of EIF2S1 protein]
Bortezomib promotes the reaction [lapatinib results in decreased phosphorylation of ERBB2 protein]; lapatinib promotes the reaction [Bortezomib results in decreased phosphorylation of ERBB2 protein]
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ERN1 mRNA; Bortezomib affects the reaction [ricolinostat affects the phosphorylation of ERN1 protein] ERN1 results in decreased susceptibility to Bortezomib
Bortezomib binds to and results in decreased activity of ESR1 protein; Bortezomib inhibits the reaction [Estradiol results in increased activity of ESR1 protein]
[Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of ESR2 mRNA; Bortezomib binds to and results in decreased activity of ESR2 protein; Bortezomib inhibits the reaction [Estradiol results in increased activity of ESR2 protein]
Bortezomib results in decreased expression of ESRRA mRNA Bortezomib inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein]; Bortezomib inhibits the reaction [XCT790 results in decreased activity of ESRRA protein]
Bortezomib results in increased expression of F3 protein [Dexamethasone co-treated with lenalidomide co-treated with Bortezomib] results in increased expression of F3 mRNA; [Dexamethasone co-treated with lenalidomide co-treated with Bortezomib] results in increased expression of F3 protein
[Bortezomib co-treated with vorinostat] results in increased expression of FAS protein Bortezomib results in decreased expression of FAS mRNA Bortezomib results in increased expression of FAS mRNA; Bortezomib results in increased expression of FAS protein
[Bortezomib co-treated with vorinostat] results in increased expression of FASLG mRNA; [Bortezomib co-treated with vorinostat] results in increased expression of FASLG protein; Bortezomib promotes the reaction [arsenic trioxide results in increased activity of FASLG]; Curcumin inhibits the reaction [[vorinostat co-treated with Bortezomib] results in increased expression of FASLG protein] Bortezomib results in increased expression of FASLG protein
Bortezomib results in increased expression of GADD45A mRNA [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GADD45A mRNA
Bortezomib results in increased expression of GADD45B mRNA Bortezomib inhibits the reaction [lipopolysaccharide A results in increased expression of GADD45B mRNA]
Bortezomib results in increased expression of GDF15 mRNA [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GDF15 mRNA
[Bortezomib co-treated with lonafarnib] results in decreased expression of GSK3B protein modified form; Bortezomib results in decreased activity of and results in increased phosphorylation of GSK3B protein; GSK3B protein mutant form inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; Wortmannin inhibits the reaction [Bortezomib results in decreased activity of and results in increased phosphorylation of GSK3B protein]
[Bortezomib co-treated with romidepsin] results in increased phosphorylation of H2AX protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with romidepsin] results in increased phosphorylation of H2AX protein]; leptomycin B promotes the reaction [Bortezomib results in increased expression of H2AX protein modified form] Bortezomib results in decreased phosphorylation of H2AX protein Bortezomib inhibits the reaction [Doxorubicin results in increased expression of H2AX protein]; Bortezomib inhibits the reaction [Etoposide results in increased expression of H2AX protein]
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of HMOX1 mRNA; [cobaltiprotoporphyrin results in increased expression of HMOX1 protein] which results in increased susceptibility to Bortezomib; abexinostat promotes the reaction [Bortezomib results in increased expression of HMOX1 mRNA] Berberine inhibits the reaction [Bortezomib results in increased expression of HMOX1 mRNA] HMOX1 protein results in increased susceptibility to Bortezomib Bortezomib results in increased expression of HMOX1 mRNA; Bortezomib results in increased expression of HMOX1 protein
ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]]; HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]
Bortezomib results in increased expression of HSF1 mRNA Bortezomib results in increased activity of HSF1 protein Bortezomib promotes the reaction [HSF1 protein binds to HSPA1A promoter]; HSF1 protein promotes the reaction [Bortezomib results in increased expression of ZFAND2A protein]
Bortezomib results in increased expression of HSF2 mRNA; Bortezomib results in increased expression of HSF2 protein HSF2 protein inhibits the reaction [Bortezomib results in increased expression of ZFAND2A protein]
Bortezomib promotes the reaction [HSF1 protein binds to HSPA1A promoter] HSPA1A protein results in decreased susceptibility to Bortezomib Bortezomib results in increased expression of HSPA1A mRNA
Bortezomib results in increased expression of HSPA1B mRNA HSPA1B protein affects the susceptibility to Bortezomib HSPA1B protein results in decreased susceptibility to Bortezomib
Bortezomib inhibits the reaction [Brefeldin A results in increased expression of HSPA5 protein]; Bortezomib inhibits the reaction [Tunicamycin results in increased expression of HSPA5 protein]; Bortezomib promotes the reaction [gambogic acid results in increased expression of HSPA5 protein]; Bortezomib promotes the reaction [geldanamycin results in increased expression of HSPA5 protein]; gambogic acid promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]; geldanamycin promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]; MYC protein promotes the reaction [Bortezomib results in increased expression of HSPA5 protein] Bortezomib results in increased expression of HSPA5 mRNA HSPA5 results in decreased susceptibility to Bortezomib Bortezomib results in increased expression of HSPA5; Bortezomib results in increased expression of HSPA5 mRNA; Bortezomib results in increased expression of HSPA5 protein
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of ICAM1 mRNA; [romidepsin co-treated with Bortezomib] results in decreased expression of ICAM1 protein Bortezomib results in decreased expression of ICAM1 mRNA
[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]]
Bortezomib inhibits the reaction [IGF2 protein results in increased expression of STS mRNA]; Bortezomib inhibits the reaction [IGF2 protein results in increased expression of STS protein] Bortezomib results in decreased susceptibility to IGF2 protein
Bortezomib promotes the reaction [abexinostat results in decreased expression of IKBKB mRNA]; IKBKB protein affects the reaction [Bortezomib results in increased phosphorylation of and results in increased degradation of NFKBIA protein] Bortezomib results in decreased expression of IKBKB mRNA
[Dexamethasone co-treated with Bortezomib] inhibits the reaction [IL6 protein results in increased expression of SOD2 mRNA]; [Dexamethasone co-treated with Bortezomib] results in decreased expression of IL6 mRNA; [Dexamethasone co-treated with Bortezomib] results in decreased secretion of IL6 protein; Bortezomib inhibits the reaction [IL6 protein results in decreased susceptibility to Dexamethasone] Bortezomib results in increased expression of IL6 mRNA Berberine inhibits the reaction [Bortezomib results in increased expression of IL6 mRNA] Bortezomib inhibits the reaction [[Chloroquine co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL6 protein]; Bortezomib inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL6 protein] Bortezomib results in decreased expression of IL6 mRNA Bortezomib results in decreased secretion of IL6 protein
Bortezomib results in increased expression of IL7R mRNA [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of IL7R mRNA
3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid promotes the reaction [Bortezomib results in decreased expression of IRF4 protein]; Bortezomib promotes the reaction [3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid results in decreased expression of IRF4 protein]
Bortezomib results in decreased expression of JUN mRNA Bortezomib results in increased expression of JUN mRNA; Bortezomib results in increased expression of JUN protein Bortezomib results in increased expression of JUN mRNA; Bortezomib results in increased expression of JUN protein; Bortezomib results in increased expression of JUN protein modified form Bortezomib results in increased phosphorylation of JUN protein [arsenic trioxide co-treated with Bortezomib] results in decreased expression of JUN mRNA; [arsenic trioxide co-treated with Bortezomib] results in increased activity of JUN protein modified form; [Bortezomib co-treated with sorafenib] results in increased phosphorylation of JUN protein; pyrazolanthrone inhibits the reaction [Bortezomib results in increased phosphorylation of JUN protein]
Bortezomib results in decreased expression of JUNB protein 3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid promotes the reaction [Bortezomib results in decreased expression of JUNB protein]; Bortezomib promotes the reaction [3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid results in decreased expression of JUNB protein]
[Bortezomib co-treated with Butyrates] results in decreased expression of MAP2K1 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of MAP2K1 protein
alvocidib promotes the reaction [Bortezomib results in increased phosphorylation of and results in increased activity of MAP2K4 protein]; Bortezomib results in increased phosphorylation of and results in increased activity of MAP2K4 protein
[Bortezomib co-treated with Butyrates] results in decreased expression of MAPK1 protein; [Bortezomib co-treated with panobinostat] results in decreased activity of MAPK1 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of MAPK1 protein; alvocidib inhibits the reaction [Bortezomib results in increased expression of MAPK1 protein modified form]; Bortezomib promotes the reaction [Curcumin results in decreased phosphorylation of MAPK1 protein]; lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK1 protein] Bortezomib results in decreased activity of MAPK1 protein
[[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK10 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK10 protein; [Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK10 protein; [Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK10 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK10 protein]; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK10 protein]
[Bortezomib co-treated with Butyrates] results in increased phosphorylation of MAPK14 protein; [Bortezomib co-treated with vorinostat] results in increased phosphorylation of MAPK14 protein; MAPK14 mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]
[Bortezomib co-treated with Butyrates] results in decreased expression of MAPK3 protein; [Bortezomib co-treated with panobinostat] results in decreased activity of MAPK3 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of MAPK3 protein; alvocidib inhibits the reaction [Bortezomib results in increased expression of MAPK3 protein modified form]; Bortezomib promotes the reaction [Curcumin results in decreased phosphorylation of MAPK3 protein]; lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK3 protein] Bortezomib results in decreased activity of MAPK3 protein
[[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK8 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK8 protein; [Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK8 protein; [Bortezomib co-treated with sorafenib] results in increased phosphorylation of MAPK8 protein; [Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK8 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK8 protein]; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK8 protein]; alvocidib promotes the reaction [Bortezomib results in increased phosphorylation of and results in increased activity of MAPK8 protein]; Bortezomib results in increased phosphorylation of and results in increased activity of MAPK8 protein; CGC 11093 promotes the reaction [Bortezomib results in increased phosphorylation of MAPK8 protein]; MAPK8 results in increased susceptibility to [Bortezomib co-treated with CGC 11093]
Bortezomib results in increased phosphorylation of MAPK9 protein [Bortezomib co-treated with arsenic trioxide] affects the expression of MAPK9 protein; [Bortezomib co-treated with sorafenib] results in increased phosphorylation of MAPK9 protein; CGC 11093 promotes the reaction [Bortezomib results in increased phosphorylation of MAPK9 protein]; MAPK9 results in increased susceptibility to [Bortezomib co-treated with CGC 11093]
[[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of MCL1 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of MCL1 protein; [Bortezomib co-treated with Butyrates] results in decreased expression of MCL1 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in decreased expression of MCL1 protein; [Bortezomib co-treated with SCIO-469] results in decreased expression of MCL1 protein; [Bortezomib co-treated with SCIO-469] results in decreased expression of MCL1 protein modified form; [Bortezomib co-treated with vorinostat] results in decreased expression of MCL1 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of MCL1 protein]; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with vorinostat] results in decreased expression of MCL1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of MCL1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with vorinostat] results in decreased expression of MCL1 protein]; romidepsin inhibits the reaction [Bortezomib results in increased expression of MCL1 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of MCL1 protein]; TNFSF10 protein inhibits the reaction [Bortezomib results in increased expression of MCL1 protein] Bortezomib inhibits the reaction [Acetaminophen results in decreased expression of MCL1 protein] MCL1 protein results in decreased susceptibility to Bortezomib; MCL1 results in decreased susceptibility to Bortezomib Bortezomib results in increased expression of MCL1; Bortezomib results in increased expression of MCL1 protein
[CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; Bortezomib promotes the reaction [TP53 protein binds to MDM2 protein] Bortezomib affects the expression of MDM2 protein
Bortezomib results in decreased expression of MKI67 protein [Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]]
Bortezomib promotes the reaction [butein results in decreased expression of MMP9 protein]; Bortezomib promotes the reaction [capillarisin results in decreased expression of MMP9 protein]
[Bortezomib co-treated with abexinostat] results in decreased expression of MYC mRNA; Bortezomib promotes the reaction [abexinostat results in decreased expression of MYC protein]; MYC protein promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]; MYC protein promotes the reaction [Bortezomib results in increased expression of PMAIP1 protein] Bortezomib results in increased expression of MYC protein Bortezomib results in decreased expression of MYC protein
[Bortezomib results in increased expression of NFE2L2 protein] which results in increased expression of CBR3 mRNA; Bortezomib results in increased expression of NFE2L2 protein Berberine inhibits the reaction [Bortezomib results in increased expression of NFE2L2 mRNA] Bortezomib results in increased activity of NFE2L2 protein
[Bortezomib co-treated with vorinostat] results in decreased activity of [NFKB1 protein binds to RELA protein]; [resveratrol co-treated with Bortezomib] results in decreased activity of [RELA protein binds to NFKB1 protein]; Bortezomib inhibits the reaction [belinostat results in increased expression of NFKB1 protein]; Bortezomib inhibits the reaction [romidepsin results in increased expression of NFKB1 protein]; Bortezomib promotes the reaction [Fenretinide inhibits the reaction [TNF protein results in increased activity of NFKB1 protein]] Bortezomib results in increased expression of NFKB1 mRNA Berberine inhibits the reaction [Bortezomib results in increased expression of NFKB1 mRNA] Bortezomib results in decreased expression of NFKB1 mRNA; Bortezomib results in decreased expression of NFKB1 protein
Bortezomib results in decreased cleavage of NFKB2 protein Bortezomib results in decreased expression of NFKB2 mRNA; Bortezomib results in decreased expression of NFKB2 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; [Bortezomib co-treated with Arsenic Trioxide] affects the expression of NFKBIA protein; [Bortezomib co-treated with TNFSF10 protein] inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; [Dexamethasone co-treated with Bortezomib] results in increased expression of NFKBIA mRNA; [Dexamethasone co-treated with Bortezomib] results in increased phosphorylation of NFKBIA protein; alvocidib promotes the reaction [Bortezomib results in increased expression of NFKBIA protein modified form]; Ammonium Chloride inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; Bortezomib inhibits the reaction [belinostat results in increased expression of NFKBIA protein]; Bortezomib inhibits the reaction [romidepsin results in increased expression of NFKBIA protein]; Bortezomib promotes the reaction [alvocidib results in increased expression of NFKBIA protein modified form]; Bortezomib results in increased phosphorylation of and results in increased degradation of NFKBIA protein; Chloroquine inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; Dexamethasone inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; GSK3B protein mutant form inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; IKBKB protein affects the reaction [Bortezomib results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; MAP1LC3B protein affects the reaction [Bortezomib results in increased phosphorylation of NFKBIA protein]; NFKBIA protein mutant form inhibits the reaction [Bortezomib results in increased expression of PTGS2 protein]; SC 514 affects the reaction [Bortezomib results in increased phosphorylation of NFKBIA protein]; SC 514 inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; Wortmannin inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein] Bortezomib results in increased stability of NFKBIA protein Bortezomib results in increased expression of NFKBIA mRNA; Bortezomib results in increased expression of NFKBIA protein modified form Bortezomib results in decreased degradation of NFKBIA protein
Bortezomib inhibits the reaction [arsenic trioxide results in decreased expression of NFKBIE mRNA] Bortezomib results in increased stability of NFKBIE protein
Bortezomib promotes the reaction [arsenic trioxide results in increased expression of NLRP12 mRNA] Bortezomib results in increased expression of NLRP12 mRNA
Bortezomib results in decreased expression of NLRP3 mRNA Bortezomib results in increased expression of NLRP3 mRNA Berberine inhibits the reaction [Bortezomib results in increased expression of NLRP3 mRNA]
Bortezomib results in increased expression of NOS1 protein Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of NOS1 protein]
Acetylcysteine inhibits the reaction [NPM1 protein mutant form results in increased susceptibility to Bortezomib] NPM1 protein affects the susceptibility to Bortezomib
Bortezomib inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein]
NUPR1 mutant form promotes the reaction [Bortezomib results in increased expression of ATF4 mRNA] Bortezomib results in increased expression of NUPR1 mRNA
[alvocidib co-treated with Bortezomib] results in increased cleavage of PARP1 protein; [Arsenic Trioxide co-treated with Bortezomib] results in increased degradation of PARP1 protein; [Bortezomib co-treated with abexinostat] results in increased activity of PARP1 protein; [Bortezomib co-treated with Butyrates] results in increased degradation of PARP1 protein; [Bortezomib co-treated with Doxorubicin] results in increased cleavage of PARP1 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in increased cleavage of PARP1 protein; [Bortezomib co-treated with Sorafenib] results in increased cleavage of PARP1 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of PARP1 protein; [Bortezomib co-treated with Vorinostat] results in increased degradation of PARP1 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of PARP1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; [Curcumin co-treated with Bortezomib] results in increased cleavage of PARP1 protein; [Dichlororibofuranosylbenzimidazole co-treated with Bortezomib] results in increased cleavage of PARP1 protein; [RB1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of PARP1 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [Bortezomib promotes the reaction [gambogic acid results in increased cleavage of PARP1 protein]]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [gambogic acid promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]]; Bortezomib promotes the reaction [belinostat results in increased cleavage of PARP1 protein]; Bortezomib promotes the reaction [capillarisin results in increased cleavage of PARP1 protein]; Bortezomib promotes the reaction [gambogic acid results in increased cleavage of PARP1 protein]; Bortezomib promotes the reaction [romidepsin results in increased cleavage of PARP1 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of PARP1 protein]; Bortezomib results in increased cleavage of and results in increased activity of PARP1 protein; gambogic acid promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]; ricolinostat promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]; TNFRSF10B mutant form inhibits the reaction [Bortezomib results in increased cleavage of PARP1 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein]; ZFAND2A protein inhibits the reaction [Bortezomib results in increased cleavage of PARP1 protein] Bortezomib results in increased expression of PARP1 protein
Bortezomib results in increased expression of PCYT1A mRNA [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PCYT1A mRNA
Bortezomib binds to and results in decreased activity of PGR protein; Bortezomib inhibits the reaction [Promegestone results in increased activity of PGR protein]
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of PMAIP1 mRNA; [Bortezomib co-treated with arsenic trioxide] results in increased expression of PMAIP1 protein; [Bortezomib co-treated with vorinostat] results in increased expression of PMAIP1 protein; [nutlin 3 co-treated with Bortezomib] results in increased expression of PMAIP1 protein; ATF3 mutant form promotes the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 protein]; Bortezomib promotes the reaction [ATF4 protein binds to PMAIP1 promoter]; MYC protein promotes the reaction [Bortezomib results in increased expression of PMAIP1 protein]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with arsenic trioxide] results in increased activity of CASP3 protein]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with vorinostat] results in increased activity of CASP4 protein] PMAIP1 protein results in increased susceptibility to Bortezomib; PMAIP1 results in increased susceptibility to Bortezomib Bortezomib results in increased expression of PMAIP1 mRNA; Bortezomib results in increased expression of PMAIP1 protein Bortezomib results in decreased expression of PMAIP1 mRNA
Bortezomib promotes the reaction [alvocidib results in decreased phosphorylation of POLR2A protein]; Bortezomib promotes the reaction [Dichlororibofuranosylbenzimidazole results in decreased phosphorylation of POLR2A protein]
[arsenic trioxide co-treated with Bortezomib] results in increased cleavage of and results in increased activity of PRKCD protein; Bortezomib promotes the reaction [NSC606985 results in increased activity of and results in increased cleavage of PRKCD protein]
[CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of PRKDC protein]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of PRKDC protein] Bortezomib results in decreased expression of PRKDC mRNA
Bortezomib binds to PSMB5 protein PSMB5 protein affects the susceptibility to Bortezomib Bortezomib results in increased expression of PSMB5 mRNA PSMB5 gene mutant form results in decreased susceptibility to Bortezomib
Bortezomib results in increased expression of PTGS2 mRNA; Bortezomib results in increased expression of PTGS2 protein Bortezomib promotes the reaction [capillarisin results in decreased expression of PTGS2 protein]; NFKBIA protein mutant form inhibits the reaction [Bortezomib results in increased expression of PTGS2 protein]
[Bortezomib co-treated with Butyrates] results in decreased expression of RAF1 protein; [Bortezomib co-treated with panobinostat] results in decreased expression of RAF1 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of RAF1 protein Bortezomib results in decreased expression of RAF1 protein
[Bortezomib co-treated with Butyrates] results in increased degradation of RB1 protein; [Bortezomib co-treated with vorinostat] results in increased degradation of RB1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein; [RB1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein]
[Bortezomib co-treated with Arsenic Trioxide] results in decreased activity of RELA protein; [Bortezomib co-treated with Doxorubicin] results in decreased phosphorylation of RELA protein; [Bortezomib co-treated with trichostatin A] results in decreased expression of and results in decreased activity of RELA protein; [Bortezomib co-treated with trichostatin A] results in decreased expression of RELA protein; [Bortezomib co-treated with Vorinostat] results in decreased activity of [NFKB1 protein binds to RELA protein]; [Resveratrol co-treated with Bortezomib] results in decreased activity of [RELA protein binds to NFKB1 protein]; Bortezomib inhibits the reaction [belinostat results in increased acetylation of RELA protein]; Bortezomib inhibits the reaction [romidepsin results in increased acetylation of RELA protein]; Bortezomib inhibits the reaction [TNF protein affects the localization of RELA protein]; Bortezomib promotes the reaction [Fenretinide inhibits the reaction [TNF protein results in increased activity of RELA protein]] Bortezomib results in decreased expression of RELA mRNA; Bortezomib results in decreased expression of RELA protein Bortezomib results in decreased activity of RELA protein
Bortezomib results in decreased expression of SIRT1 protein Berberine inhibits the reaction [Bortezomib results in decreased expression of SIRT1 protein]
Bortezomib results in decreased expression of SKP2 protein Cisplatin promotes the reaction [Bortezomib results in decreased expression of SKP2 protein]
[Bortezomib inhibits the reaction [Cisplatin results in decreased expression of SLC31A1 protein]] which results in increased uptake of Cisplatin; [Bortezomib results in decreased degradation of SLC31A1 protein] which results in increased uptake of Platinum; Bortezomib inhibits the reaction [Cisplatin results in decreased expression of SLC31A1 protein]
[Dexamethasone co-treated with Bortezomib] inhibits the reaction [IL6 protein results in increased expression of SOD2 mRNA]; [Dexamethasone co-treated with Bortezomib] results in decreased expression of SOD2 mRNA SOD2 gene SNP results in increased susceptibility to Bortezomib
[alvocidib co-treated with Bortezomib] results in decreased phosphorylation of and results in decreased activity of STAT3 protein; [resveratrol co-treated with Bortezomib] results in decreased phosphorylation of STAT3 protein; Bortezomib promotes the reaction [Capsaicin results in decreased phosphorylation of and results in decreased activity of STAT3 protein]; Bortezomib promotes the reaction [Curcumin results in decreased phosphorylation of STAT3 protein]; Bortezomib results in increased expression of and results in increased phosphorylation of STAT3 protein Berberine inhibits the reaction [Bortezomib results in increased expression of STAT3 mRNA]
Bortezomib inhibits the reaction [2-chloroethyl ethyl sulfide results in decreased expression of and results in decreased phosphorylation of STK11 protein]; Bortezomib inhibits the reaction [geldanamycin results in decreased expression of and results in decreased phosphorylation of STK11 protein]
Bortezomib results in increased activity of and results in increased localization of STK4 protein; leptomycin B promotes the reaction [Bortezomib results in increased activity of STK4 protein]; STK4 mutant form inhibits the reaction [Bortezomib results in increased activity of CASP3 protein] STK4 protein results in increased susceptibility to Bortezomib; STK4 results in increased susceptibility to Bortezomib
Bortezomib inhibits the reaction [IGF2 protein results in increased expression of STS mRNA]; Bortezomib inhibits the reaction [IGF2 protein results in increased expression of STS protein] Bortezomib results in decreased expression of STS mRNA
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of THRA mRNA; Bortezomib binds to and results in decreased activity of THRA protein
Bortezomib promotes the reaction [arsenic trioxide results in increased expression of TICAM2 mRNA] Bortezomib results in increased expression of TICAM2 mRNA
Bortezomib inhibits the reaction [arsenic trioxide results in decreased expression of TLR2 mRNA] Bortezomib results in increased expression of TLR2 mRNA
[Arsenic Trioxide co-treated with Bortezomib] results in increased expression of TNF protein; [Bortezomib co-treated with TNFSF10 protein] inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; Bortezomib inhibits the reaction [TNF protein affects the localization of RELA protein]; Bortezomib promotes the reaction [Fenretinide inhibits the reaction [TNF protein results in increased activity of NFKB1 protein]]; Bortezomib promotes the reaction [Fenretinide inhibits the reaction [TNF protein results in increased activity of RELA protein]] Bortezomib results in increased expression of TNF mRNA Berberine inhibits the reaction [Bortezomib results in increased expression of TNF mRNA] Bortezomib inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of TNF protein]; Bortezomib inhibits the reaction [TNF protein results in increased activity of UPP1 protein]; Bortezomib inhibits the reaction [TNF protein results in increased expression of UPP1 mRNA]
Bortezomib affects the expression of TNFRSF10A mRNA; Bortezomib affects the expression of TNFRSF10A protein Bortezomib results in increased localization of TNFRSF10A protein Bortezomib results in increased expression of TNFRSF10A protein Bortezomib results in decreased expression of TNFRSF10A protein [Bortezomib co-treated with arsenic trioxide] results in increased expression of TNFRSF10A protein; [Bortezomib results in increased localization of TNFRSF10A protein] promotes the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; Brefeldin A inhibits the reaction [Bortezomib results in increased localization of TNFRSF10A protein]
[Arsenic Trioxide co-treated with Bortezomib] results in increased expression of TNFSF10 mRNA; [Bortezomib co-treated with TNFSF10 protein] inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; [Bortezomib co-treated with TNFSF10 protein] results in decreased expression of CFLAR protein; [Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of BID protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased expression of DIABLO protein; [Bortezomib results in increased localization of TNFRSF10A protein] promotes the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; [Bortezomib results in increased localization of TNFRSF10B protein] promotes the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of BID protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP3 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP8 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP9 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of PARP1 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased activity of CASP3 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of BID protein; [TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased expression of CDKN1A protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein]; BAK1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; BCL2 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; BCL2L1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; Bortezomib inhibits the reaction [BAX mutant form inhibits the reaction [TNFSF10 protein results in increased localization of DIABLO protein]]; Bortezomib inhibits the reaction [TNFSF10 protein results in increased activity of AKT1 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of BID protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of CASP6 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of CASP8 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of XIAP protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased localization of DIABLO protein]; Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein; Brefeldin A affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; CDKN1A protein affects the reaction [[TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein]; TNFRSF10B mutant form inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein]; TNFRSF10B mutant form inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]; TNFSF10 protein inhibits the reaction [Bortezomib results in increased expression of CTNNB1 protein]; TNFSF10 protein inhibits the reaction [Bortezomib results in increased expression of MCL1 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in decreased expression of CFLAR protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased activity of CASP3 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased cleavage of CASP9 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased cleavage of XIAP protein] BAK1 protein results in increased susceptibility to [Bortezomib co-treated with TNFSF10 protein] Bortezomib results in decreased expression of TNFSF10 mRNA; Bortezomib results in decreased expression of TNFSF10 protein
Bortezomib inhibits the reaction [4,4'-(1,2-dimethyl-1,2-ethanediyl)bis-2,6-piperazinedione results in increased degradation of and results in decreased expression of TOP2B protein]; Bortezomib inhibits the reaction [Razoxane results in increased degradation of and results in decreased expression of TOP2B protein]
Bortezomib results in increased expression of TP53 protein Bortezomib affects the activity of TP53 protein Bortezomib results in increased activity of TP53 protein [SCIO-469 co-treated with Bortezomib] results in increased expression of TRP53 protein [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; [irinotecan co-treated with Bortezomib] results in increased ubiquitination of TP53 protein; [vorinostat co-treated with Bortezomib] results in increased expression of TP53 protein; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; Bortezomib promotes the reaction [TP53 protein binds to MDM2 protein]; Bortezomib results in increased phosphorylation of and results in increased localization of TP53 protein; Caffeine inhibits the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased expression of TP53 protein]; TP53 protein affects the susceptibility to [irinotecan co-treated with Bortezomib] Bortezomib results in increased stability of TP53 protein
TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein]; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein]
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of TRIB3 protein]; [Bortezomib co-treated with Chloroquine] results in increased expression of TRIB3 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TRIB3 mRNA; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of TRIB3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of TRIB3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of TRIB3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of TRIB3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of TRIB3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased expression of TRIB3 protein] 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of TRIB3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of TRIB3 protein]; [Bortezomib co-treated with Chloroquine] results in increased expression of TRIB3 protein; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of TRIB3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of TRIB3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of TRIB3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of TRIB3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of TRIB3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased expression of TRIB3 protein]
Bortezomib inhibits the reaction [TNF protein results in increased activity of UPP1 protein]; Bortezomib inhibits the reaction [TNF protein results in increased expression of UPP1 mRNA] Bortezomib results in decreased activity of UPP1 protein
Bortezomib results in decreased expression of VEGFA protein [Curcumin co-treated with Bortezomib] results in decreased expression of VEGFA protein; Bortezomib promotes the reaction [docetaxel results in decreased expression of VEGFA protein]; CGC 11093 promotes the reaction [Bortezomib results in decreased expression of VEGFA protein]; docetaxel promotes the reaction [Bortezomib results in decreased expression of VEGFA protein]
[ricolinostat co-treated with Bortezomib] results in increased expression of XBP1 protein alternative form; Bortezomib inhibits the reaction [Brefeldin A results in increased activity of XBP1 protein] Bortezomib results in increased expression of XBP1 protein alternative form Bortezomib results in increased activity of XBP1 protein
[[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of XIAP protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of XIAP protein; [Bortezomib co-treated with Butyrates] results in decreased expression of XIAP protein; [Bortezomib co-treated with vorinostat] results in decreased expression of XIAP protein; [romidepsin co-treated with Bortezomib] results in decreased expression of XIAP protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of XIAP protein]; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with vorinostat] results in decreased expression of XIAP protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of XIAP protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with vorinostat] results in decreased expression of XIAP protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of XIAP protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased cleavage of XIAP protein] Bortezomib results in increased expression of XIAP mRNA; Bortezomib results in increased expression of XIAP protein Bortezomib affects the expression of XIAP protein Bortezomib results in decreased expression of XIAP protein
Bortezomib results in increased expression of ZFAND2A mRNA; Bortezomib results in increased expression of ZFAND2A protein ZFAND2A protein results in decreased susceptibility to Bortezomib Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP3 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP7 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP8 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP9 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of PARP1 protein]; HSF1 protein promotes the reaction [Bortezomib results in increased expression of ZFAND2A protein]; HSF2 protein inhibits the reaction [Bortezomib results in increased expression of ZFAND2A protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP7 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP8 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP9 protein]; ZFAND2A protein inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; ZFAND2A protein inhibits the reaction [Bortezomib results in increased cleavage of PARP1 protein]
BRCA2 protein affects the susceptibility to CX 5461 BRCA2 protein affects the reaction [CX 5461 results in increased expression of TP53BP1 protein]; BRCA2 protein affects the reaction [CX 5461 results in increased phosphorylation of RPA2 protein]
CX 5461 results in increased phosphorylation of RPA2 protein BRCA2 protein affects the reaction [CX 5461 results in increased phosphorylation of RPA2 protein]
ethylisopropylamiloride binds to AOC1 protein Ethylisopropylamiloride binds to Aoc1 protein Ethylisopropylamiloride inhibits the reaction [Phenylamil binds to Aoc1 protein] ethylisopropylamiloride results in decreased activity of AOC1 protein ethylisopropylamiloride inhibits the reaction [AOC1 protein results in increased degradation of Putrescine]
ethylisopropylamiloride inhibits the reaction [ferric nitrilotriacetate results in increased expression of COL1A1 protein]; ethylisopropylamiloride inhibits the reaction [iron(II)-ascorbic acid complex results in increased expression of COL1A1 protein]
ethylisopropylamiloride inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with IFNG protein] results in increased secretion of IL12B protein]
ethylisopropylamiloride inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with IFNG protein] results in increased secretion of IL12B protein]
ethylisopropylamiloride inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of and results in increased activity of NFKB1 protein]
ethylisopropylamiloride inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of and results in increased activity of RELA protein]
ethylisopropylamiloride results in decreased activity of SLC9A1 protein [ethylisopropylamiloride results in decreased activity of SLC9A1 protein] which results in increased abundance of Doxorubicin
Glipizide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Glipizide results in decreased activity of ABCB11 protein
LGK974 inhibits the reaction [Paraquat affects the localization of CTNNB1 protein]; LGK974 inhibits the reaction [Paraquat results in increased expression of and results in decreased phosphorylation of CTNNB1 protein]
[Lithocholic Acid co-treated with oltipraz] results in increased expression of ABCC2 protein; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC2 mRNA oltipraz results in increased expression of ABCC2 mRNA; oltipraz results in increased expression of ABCC2 protein
oltipraz results in increased expression of ABCC3 mRNA [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC3 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of ABCC3 mRNA]; NFE2L2 protein promotes the reaction [oltipraz results in increased expression of ABCC3 mRNA] [oltipraz results in increased expression of ABCC3 protein] which affects the export of Acetaminophen metabolite oltipraz results in increased expression of ABCC3 mRNA; oltipraz results in increased expression of ABCC3 protein
[Lithocholic Acid co-treated with oltipraz] results in increased expression of ABCC4 protein; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC4 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of ABCC4 mRNA] oltipraz results in increased expression of ABCC4 mRNA; oltipraz results in increased expression of ABCC4 protein oltipraz promotes the reaction [ABCC4 protein results in increased transport of Arsenic]
[Lithocholic Acid co-treated with oltipraz] results in increased expression of ABCC5 protein; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC5 mRNA oltipraz results in increased expression of ABCC5 mRNA
[oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC6 mRNA oltipraz results in increased expression of ABCC6 mRNA
oltipraz promotes the reaction [ABCG2 protein results in increased transport of Benzo(a)pyrene metabolite] oltipraz results in increased expression of ABCG2 mRNA oltipraz results in increased activity of ABCG2 protein
oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE protein]] oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in increased expression of ACE mRNA]]
oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in decreased expression of ACE2 mRNA]] oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 protein]]
oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in increased expression of AGT mRNA]] oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT protein]]
[oltipraz promotes the reaction [AHR protein binds to CYP1A1 promoter]] which results in increased expression of CYP1A1 mRNA; oltipraz promotes the reaction [AHR protein binds to CYP1A1 promoter]; resveratrol inhibits the reaction [[oltipraz promotes the reaction [AHR protein binds to CYP1A1 promoter]] which results in increased expression of CYP1A1 mRNA] oltipraz results in increased activity of AHR protein
[oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ALDH1A1 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of ALDH1A1 mRNA]
[Lithocholic Acid co-treated with oltipraz] results in increased expression of BAX mRNA oltipraz inhibits the reaction [Acetaminophen results in increased expression of BAX protein]
[Dexamethasone co-treated with oltipraz] results in increased activity of CEBPB protein; N-acetylsphingosine inhibits the reaction [oltipraz results in increased localization of CEBPB protein]; oltipraz promotes the reaction [CEBPB protein binds to GSTA2 promoter]; oltipraz results in increased localization of and results in increased activity of CEBPB protein
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [oltipraz results in increased expression of CYP1A1 mRNA]; 2-aminoethoxydiphenyl borate inhibits the reaction [[oltipraz results in increased abundance of Calcium] which results in increased expression of CYP1A1 mRNA]; [oltipraz promotes the reaction [AHR protein binds to CYP1A1 promoter]] which results in increased expression of CYP1A1 mRNA; [oltipraz results in increased abundance of Calcium] which results in increased expression of CYP1A1 mRNA; oltipraz promotes the reaction [AHR protein binds to CYP1A1 promoter]; oltipraz results in increased expression of and results in increased activity of CYP1A1 protein; resveratrol inhibits the reaction [[oltipraz promotes the reaction [AHR protein binds to CYP1A1 promoter]] which results in increased expression of CYP1A1 mRNA]; resveratrol inhibits the reaction [oltipraz results in increased expression of CYP1A1 mRNA] CYP1A1 protein affects the metabolism of oltipraz oltipraz results in increased expression of CYP1A1 mRNA; oltipraz results in increased expression of CYP1A1 protein oltipraz metabolite results in decreased activity of CYP1A1 protein oltipraz affects the activity of CYP1A1 protein
oltipraz metabolite results in decreased activity of CYP1A2 protein; oltipraz results in decreased activity of CYP1A2 protein oltipraz results in increased expression of CYP1A2 mRNA NFE2L2 protein affects the reaction [oltipraz results in increased expression of CYP1A2 mRNA] oltipraz results in increased activity of CYP1A2 protein oltipraz inhibits the reaction [CYP1A2 results in increased activity of 2-amino-3,4-dimethylimidazo(4,5-f)quinoline] CYP1A2 protein affects the metabolism of oltipraz
oltipraz metabolite results in decreased activity of CYP1B1 protein oltipraz affects the activity of CYP1B1 protein oltipraz results in increased expression of CYP1B1 mRNA
oltipraz results in decreased activity of CYP2B6 protein oltipraz results in increased expression of CYP2B10 mRNA oltipraz results in increased expression of CYP2B6 mRNA; oltipraz results in increased expression of CYP2B6 protein
CYP3A2 protein affects the metabolism of oltipraz oltipraz metabolite results in decreased activity of CYP3A4 protein; oltipraz results in decreased activity of CYP3A4 protein oltipraz affects the activity of CYP3A4 protein
oltipraz inhibits the reaction [Acetaminophen results in decreased expression of and results in increased secretion of GSTA1 protein]; oltipraz inhibits the reaction [Acetaminophen results in decreased expression of GSTA1 mRNA]; oltipraz inhibits the reaction [Acetaminophen results in decreased expression of GSTA1 protein]
oltipraz results in increased expression of GSTA2 mRNA; oltipraz results in increased expression of GSTA2 protein 2-tert-butylhydroquinone inhibits the reaction [oltipraz results in increased expression of GSTA2 mRNA]; Dexamethasone inhibits the reaction [oltipraz results in increased expression of GSTA2 mRNA]; Dexamethasone inhibits the reaction [oltipraz results in increased expression of GSTA2 protein]; N-acetylsphingosine inhibits the reaction [oltipraz results in increased expression of GSTA2 protein]; oltipraz promotes the reaction [CEBPB protein binds to GSTA2 promoter]
oltipraz results in increased activity of GSTA5 protein oltipraz results in increased expression of GSTA5 mRNA; oltipraz results in increased expression of GSTA5 protein
[oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM1 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM1 mRNA]
[oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM2 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM2 mRNA]
[oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM4 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM4 mRNA]
[oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM3 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM3 mRNA] oltipraz results in increased expression of GSTM3 protein
oltipraz results in increased expression of GSTP1 mRNA oltipraz results in increased expression of GSTP1 protein oltipraz results in increased expression of and results in increased activity of GSTP1 protein
oltipraz inhibits the reaction [Acetaminophen results in decreased expression of HNF1A mRNA]; oltipraz inhibits the reaction [Acetaminophen results in decreased expression of HNF1A protein]
oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 protein]]; oltipraz inhibits the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 mRNA]]
oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 protein]] oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in decreased expression of MAS1 mRNA]]
[oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of MGST3 mRNA oltipraz results in increased expression of MGST3 mRNA
oltipraz affects the activity of NFE2L2 protein oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in increased expression of NFE2L2 protein]] oltipraz results in increased activity of NFE2L2 protein [oltipraz co-treated with NFE2L2 protein mutant form] affects the expression of ABCG5 mRNA; [oltipraz co-treated with NFE2L2 protein mutant form] results in decreased expression of UGT2B1 mRNA; [oltipraz co-treated with NFE2L2 protein mutant form] results in decreased expression of UGT2B35 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC2 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC3 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC4 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC5 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC6 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ALDH1A1 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTA1 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTA4 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM1 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM2 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM3 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM4 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of MGST3 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of NQO1 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of ABCC3 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of ABCC4 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of ALDH1A1 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of CES1G mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of CES2C mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of CYP1A2 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTA1 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTA4 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM1 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM2 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM3 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM4 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of NQO1 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of SULT3A1 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of UGT1A6A mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of UGT2B34 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of UGT2B36 mRNA]; NFE2L2 protein promotes the reaction [oltipraz results in increased expression of ABCC3 mRNA]; NFE2L2 protein promotes the reaction [oltipraz results in increased expression of CES1 mRNA]; NFE2L2 protein promotes the reaction [oltipraz results in increased expression of NQO1 mRNA]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 protein]]; oltipraz binds to and results in increased activity of NFE2L2 protein; oltipraz inhibits the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 mRNA]] NFE2L2 protein affects the susceptibility to oltipraz
oltipraz results in increased activity of NQO1 protein oltipraz promotes the reaction [Cisplatin results in increased expression of NQO1 mRNA] oltipraz metabolite results in increased expression of NQO1 protein; oltipraz results in increased expression of NQO1 mRNA; oltipraz results in increased expression of NQO1 protein [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of NQO1 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of NQO1 mRNA]; NFE2L2 protein promotes the reaction [oltipraz results in increased expression of NQO1 mRNA]; oltipraz promotes the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of NQO1 mRNA]
oltipraz inhibits the reaction [Butylhydroxybutylnitrosamine results in decreased expression of UGT1A6 mRNA] oltipraz results in increased expression of UGT1A6 mRNA
oltipraz results in decreased expression of UGT2B1 mRNA [oltipraz co-treated with NFE2L2 protein mutant form] results in decreased expression of UGT2B1 mRNA
oltipraz results in increased expression of UGT2B34 mRNA NFE2L2 protein affects the reaction [oltipraz results in increased expression of UGT2B34 mRNA]
phenylamil results in increased expression of ADIPOQ mRNA PPARG protein promotes the reaction [phenylamil results in increased expression of ADIPOQ mRNA]
phenylamil inhibits the reaction [AOC1 protein results in increased degradation of Putrescine] Phenylamil binds to Aoc1 protein phenylamil results in decreased activity of AOC1 protein phenylamil binds to AOC1 protein
[phenylamil co-treated with Harmine] results in increased expression of FABP4 mRNA; PPARG protein promotes the reaction [phenylamil results in increased expression of FABP4 mRNA]
[phenylamil co-treated with Harmine] results in increased expression of PPARG mRNA; PPARG protein promotes the reaction [phenylamil results in increased expression of ADIPOQ mRNA]; PPARG protein promotes the reaction [phenylamil results in increased expression of AQP7 mRNA]; PPARG protein promotes the reaction [phenylamil results in increased expression of FABP4 mRNA] PPARG protein affects the susceptibility to phenylamil phenylamil results in increased expression of PPARG mRNA
Pyrazinamide results in decreased expression of ABCB11 mRNA; Pyrazinamide results in decreased expression of ABCB11 protein [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCB11 protein obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of ABCB11 mRNA]
obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of ABCB4 mRNA] Pyrazinamide results in decreased expression of ABCB4 mRNA; Pyrazinamide results in decreased expression of ABCB4 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCC2 protein; obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of ABCC2 mRNA] Pyrazinamide results in decreased expression of ABCC2 mRNA; Pyrazinamide results in decreased expression of ABCC2 protein
Pyrazinamide results in increased expression of ACAA1 mRNA Fenofibrate promotes the reaction [Pyrazinamide results in increased expression of ACAA1 mRNA]; Pyrazinamide promotes the reaction [Fenofibrate results in increased expression of ACAA1 mRNA]
4-phenylbutyric acid inhibits the reaction [Pyrazinamide results in increased expression of ATF4 protein] Pyrazinamide results in increased expression of ATF4 mRNA; Pyrazinamide results in increased expression of ATF4 protein
Pyrazinamide results in increased cleavage of CASP3 protein [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CASP3
Pyrazinamide results in decreased expression of CAT protein [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CAT protein
Pyrazinamide results in decreased expression of CPT1B mRNA Fenofibrate inhibits the reaction [Pyrazinamide results in decreased expression of CPT1B mRNA]
[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein; [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]
[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]
Pyrazinamide results in increased expression of CYP7A1 mRNA; Pyrazinamide results in increased expression of CYP7A1 protein [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CYP7A1 protein [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CYP7A1 protein
Pyrazinamide results in decreased expression of CYP8B1 mRNA; Pyrazinamide results in decreased expression of CYP8B1 protein Pyrazinamide results in increased expression of CYP8B1 mRNA
4-phenylbutyric acid inhibits the reaction [Pyrazinamide results in increased expression of DDIT3 protein] Pyrazinamide results in increased expression of DDIT3 mRNA; Pyrazinamide results in increased expression of DDIT3 protein
Pyrazinamide results in increased phosphorylation of EIF2S1 protein 4-phenylbutyric acid inhibits the reaction [Pyrazinamide results in increased phosphorylation of EIF2S1 protein]
Pyrazinamide results in increased expression of GPT protein Pyrazinamide results in increased activity of GPT protein 4-phenylbutyric acid inhibits the reaction [Pyrazinamide results in increased expression of GPT protein]; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPT protein; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein; Fenofibrate inhibits the reaction [Pyrazinamide results in increased expression of GPT protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]
4-phenylbutyric acid inhibits the reaction [Pyrazinamide results in increased expression of HSPA5 protein] Pyrazinamide results in increased expression of HSPA5 mRNA; Pyrazinamide results in increased expression of HSPA5 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of NR1H4; obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of NR1H4 mRNA] Pyrazinamide results in decreased expression of NR1H4 mRNA; Pyrazinamide results in decreased expression of NR1H4 protein
[Pyrazinamide co-treated with Glucose] binds to PPARA protein; Pyrazinamide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]] Fenofibrate inhibits the reaction [Pyrazinamide results in decreased expression of PPARA mRNA] Pyrazinamide results in decreased expression of PPARA mRNA; Pyrazinamide results in decreased expression of PPARA protein
Pyrazinamide results in increased expression of SLC10A1 mRNA; Pyrazinamide results in increased expression of SLC10A1 protein [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of SLC10A1
obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of SLC51B mRNA] Pyrazinamide results in decreased expression of SLC51B mRNA; Pyrazinamide results in decreased expression of SLC51B protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]
Pyrazinamide results in decreased expression of SLCO1B2 mRNA; Pyrazinamide results in decreased expression of SLCO1B2 protein obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of SLCO1B2 mRNA]
INCB057643 promotes the reaction [selinexor results in decreased expression of MYC mRNA]; INCB057643 promotes the reaction [selinexor results in decreased expression of MYC protein]; selinexor promotes the reaction [INCB057643 results in decreased expression of MYC mRNA]; selinexor promotes the reaction [INCB057643 results in decreased expression of MYC protein] selinexor results in decreased expression of MYC mRNA; selinexor results in decreased expression of MYC protein
tetramethylpyrazine inhibits the reaction [Hydrogen Peroxide results in increased expression of ACTA2 mRNA] NFE2L2 affects the reaction [tetramethylpyrazine inhibits the reaction [Ethanol results in increased expression of ACTA2 protein]]; NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 mRNA]]; NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein]]; tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 mRNA]; tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein]; tetramethylpyrazine inhibits the reaction [Ethanol results in increased expression of ACTA2 protein]; tetramethylpyrazine inhibits the reaction [Paraquat results in increased expression of ACTA2 protein] tetramethylpyrazine results in decreased expression of ACTA2 mRNA; tetramethylpyrazine results in decreased expression of ACTA2 protein NFE2L2 protein promotes the reaction [tetramethylpyrazine results in decreased expression of ACTA2 mRNA]; NFE2L2 protein promotes the reaction [tetramethylpyrazine results in decreased expression of ACTA2 protein]
tetramethylpyrazine inhibits the reaction [Paraquat results in decreased expression of AKT1 mRNA]; tetramethylpyrazine inhibits the reaction [Paraquat results in decreased phosphorylation of AKT1 protein]
tetramethylpyrazine inhibits the reaction [Gentamicins results in decreased expression of BCL2L1 protein] tetramethylpyrazine inhibits the reaction [sodium arsenite results in decreased expression of BCL2L1 protein]
tetramethylpyrazine affects the reaction [Paraquat affects the expression of BECN1 protein]; tetramethylpyrazine inhibits the reaction [Paraquat results in decreased expression of BECN1 mRNA]
tetramethylpyrazine inhibits the reaction [Gentamicins results in increased activity of CASP3 protein] DDAH2 promotes the reaction [tetramethylpyrazine inhibits the reaction [Iron-Dextran Complex results in increased expression of CASP3 protein modified form]]; tetramethylpyrazine inhibits the reaction [Iron-Dextran Complex results in increased expression of CASP3 protein modified form]
tetramethylpyrazine inhibits the reaction [Gentamicins results in increased activity of CASP8 protein]; tetramethylpyrazine inhibits the reaction [TNF protein promotes the reaction [Gentamicins results in increased expression of CASP8 protein]]
tetramethylpyrazine inhibits the reaction [Gentamicins results in increased activity of CASP9 protein] tetramethylpyrazine inhibits the reaction [sodium arsenite results in decreased expression of CASP9 protein]
tetramethylpyrazine results in increased activity of CAT protein DDAH2 promotes the reaction [tetramethylpyrazine inhibits the reaction [Iron-Dextran Complex results in decreased activity of CAT protein]]; tetramethylpyrazine inhibits the reaction [Iron-Dextran Complex results in decreased activity of CAT protein]
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [tetramethylpyrazine results in increased activity of CFTR protein]; 3-((3-trifluoromethyl)phenyl)-5-((3-carboxyphenyl)methylene)-2-thioxo-4-thiazolidinone inhibits the reaction [tetramethylpyrazine results in increased activity of CFTR protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [tetramethylpyrazine results in increased activity of CFTR protein]; RMI 12330A inhibits the reaction [tetramethylpyrazine results in increased activity of CFTR protein]
tetramethylpyrazine inhibits the reaction [Hydrogen Peroxide results in increased expression of COL1A1 mRNA] NFE2L2 affects the reaction [tetramethylpyrazine inhibits the reaction [Ethanol results in increased expression of COL1A1 protein]]; NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of COL1A1 mRNA]]; NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of COL1A1 protein]]; tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of COL1A1 mRNA]; tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of COL1A1 protein]; tetramethylpyrazine inhibits the reaction [Ethanol results in increased expression of COL1A1 protein] NFE2L2 protein promotes the reaction [tetramethylpyrazine results in decreased expression of COL1A1 mRNA]; NFE2L2 protein promotes the reaction [tetramethylpyrazine results in decreased expression of COL1A1 protein] tetramethylpyrazine results in decreased expression of COL1A1 mRNA; tetramethylpyrazine results in decreased expression of COL1A1 protein
NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of COL3A1 protein]]; tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of COL3A1 protein]
NFE2L2 protein promotes the reaction [tetramethylpyrazine results in decreased expression of CTNNB1 mRNA]; NFE2L2 protein promotes the reaction [tetramethylpyrazine results in decreased expression of CTNNB1 protein]; tetramethylpyrazine inhibits the reaction [sodium arsenite results in increased expression of CTNNB1 protein] NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of CTNNB1 protein]]; tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of CTNNB1 protein] tetramethylpyrazine results in decreased expression of CTNNB1 mRNA; tetramethylpyrazine results in decreased expression of CTNNB1 protein
DDAH2 promotes the reaction [tetramethylpyrazine inhibits the reaction [Iron-Dextran Complex results in decreased abundance of Nitric Oxide]]; DDAH2 promotes the reaction [tetramethylpyrazine inhibits the reaction [Iron-Dextran Complex results in decreased activity of CAT protein]]; DDAH2 promotes the reaction [tetramethylpyrazine inhibits the reaction [Iron-Dextran Complex results in decreased phosphorylation of NOS3 protein]]; DDAH2 promotes the reaction [tetramethylpyrazine inhibits the reaction [Iron-Dextran Complex results in increased abundance of Malondialdehyde]]; DDAH2 promotes the reaction [tetramethylpyrazine inhibits the reaction [Iron-Dextran Complex results in increased abundance of N,N-dimethylarginine]]; DDAH2 promotes the reaction [tetramethylpyrazine inhibits the reaction [Iron-Dextran Complex results in increased abundance of Reactive Oxygen Species]]; DDAH2 promotes the reaction [tetramethylpyrazine inhibits the reaction [Iron-Dextran Complex results in increased expression of CASP3 protein modified form]]; tetramethylpyrazine inhibits the reaction [[Iron-Dextran Complex results in decreased expression of DDAH2 protein] which results in increased abundance of N,N-dimethylarginine]; tetramethylpyrazine inhibits the reaction [Iron-Dextran Complex results in decreased expression of DDAH2 protein]
NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of EGFR mRNA]]; NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of EGFR protein]]; tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of EGFR mRNA]; tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of EGFR protein]
tetramethylpyrazine inhibits the reaction [Hydrogen Peroxide results in increased expression of FN1 mRNA] NFE2L2 affects the reaction [tetramethylpyrazine inhibits the reaction [Ethanol results in increased expression of FN1 protein]]; NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of FN1 mRNA]]; NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of FN1 protein]]; tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of FN1 mRNA]; tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of FN1 protein]; tetramethylpyrazine inhibits the reaction [Ethanol results in increased expression of FN1 protein] tetramethylpyrazine results in decreased expression of FN1 mRNA; tetramethylpyrazine results in decreased expression of FN1 protein NFE2L2 protein promotes the reaction [tetramethylpyrazine results in decreased expression of FN1 mRNA]; NFE2L2 protein promotes the reaction [tetramethylpyrazine results in decreased expression of FN1 protein]
tetramethylpyrazine analog results in increased expression of GCLC mRNA; tetramethylpyrazine analog results in increased expression of GCLC protein NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLC mRNA]]; NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLC protein]]; tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLC mRNA]; tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLC protein]
NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLM mRNA]]; NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLM protein]]; tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLM mRNA]; tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLM protein]
tetramethylpyrazine inhibits the reaction [Paraquat results in increased expression of GLI1 mRNA]; tetramethylpyrazine inhibits the reaction [Paraquat results in increased expression of GLI1 protein]
NFE2L2 affects the reaction [tetramethylpyrazine inhibits the reaction [Ethanol results in increased expression of HIF1A mRNA]]; NFE2L2 affects the reaction [tetramethylpyrazine inhibits the reaction [Ethanol results in increased expression of HIF1A protein]]; tetramethylpyrazine inhibits the reaction [Ethanol results in increased expression of HIF1A mRNA]; tetramethylpyrazine inhibits the reaction [Ethanol results in increased expression of HIF1A protein]
tetramethylpyrazine analog results in increased expression of HMOX1 mRNA; tetramethylpyrazine analog results in increased expression of HMOX1 protein; tetramethylpyrazine results in increased expression of HMOX1 mRNA tetramethylpyrazine inhibits the reaction [sodium arsenite results in increased expression of HMOX1 protein]; tetramethylpyrazine results in increased expression of and results in increased activity of HMOX1 protein
NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of IFNG protein]]; tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of IFNG protein]
NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of IL6 protein]]; tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of IL6 protein]
[tetramethylpyrazine affects the expression of JUN mRNA] which results in decreased susceptibility to Methylnitrosourea tetramethylpyrazine inhibits the reaction [sodium arsenite results in increased expression of JUN protein modified form]
tetramethylpyrazine inhibits the reaction [Paraquat results in increased expression of MTOR mRNA]; tetramethylpyrazine inhibits the reaction [Paraquat results in increased phosphorylation of MTOR protein]
NFE2L2 protein promotes the reaction [tetramethylpyrazine results in decreased expression of ACTA2 mRNA]; NFE2L2 protein promotes the reaction [tetramethylpyrazine results in decreased expression of ACTA2 protein]; NFE2L2 protein promotes the reaction [tetramethylpyrazine results in decreased expression of COL1A1 mRNA]; NFE2L2 protein promotes the reaction [tetramethylpyrazine results in decreased expression of COL1A1 protein]; NFE2L2 protein promotes the reaction [tetramethylpyrazine results in decreased expression of CTNNB1 mRNA]; NFE2L2 protein promotes the reaction [tetramethylpyrazine results in decreased expression of CTNNB1 protein]; NFE2L2 protein promotes the reaction [tetramethylpyrazine results in decreased expression of FN1 mRNA]; NFE2L2 protein promotes the reaction [tetramethylpyrazine results in decreased expression of FN1 protein]; tetramethylpyrazine inhibits the reaction [sodium arsenite results in increased expression of NFE2L2 protein] NFE2L2 affects the susceptibility to tetramethylpyrazine NFE2L2 protein results in increased susceptibility to tetramethylpyrazine NFE2L2 affects the reaction [tetramethylpyrazine inhibits the reaction [Ethanol results in decreased expression of PPARA mRNA]]; NFE2L2 affects the reaction [tetramethylpyrazine inhibits the reaction [Ethanol results in decreased expression of PPARA protein]]; NFE2L2 affects the reaction [tetramethylpyrazine inhibits the reaction [Ethanol results in increased expression of ACTA2 protein]]; NFE2L2 affects the reaction [tetramethylpyrazine inhibits the reaction [Ethanol results in increased expression of COL1A1 protein]]; NFE2L2 affects the reaction [tetramethylpyrazine inhibits the reaction [Ethanol results in increased expression of FN1 protein]]; NFE2L2 affects the reaction [tetramethylpyrazine inhibits the reaction [Ethanol results in increased expression of HIF1A mRNA]]; NFE2L2 affects the reaction [tetramethylpyrazine inhibits the reaction [Ethanol results in increased expression of HIF1A protein]]; NFE2L2 affects the reaction [tetramethylpyrazine inhibits the reaction [Ethanol results in increased expression of RELA protein]]; NFE2L2 affects the reaction [tetramethylpyrazine inhibits the reaction [Ethanol results in increased expression of SREBF1 mRNA]]; NFE2L2 affects the reaction [tetramethylpyrazine inhibits the reaction [Ethanol results in increased expression of SREBF1 protein]]; NFE2L2 affects the reaction [tetramethylpyrazine inhibits the reaction [Ethanol results in increased expression of TNF protein]]; NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLC mRNA]]; NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLC protein]]; NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLM mRNA]]; NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLM protein]]; NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in decreased expression of NFKBIA protein]]; NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 mRNA]]; NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein]]; NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of COL1A1 mRNA]]; NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of COL1A1 protein]]; NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of COL3A1 protein]]; NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of CTNNB1 protein]]; NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of EGFR mRNA]]; NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of EGFR protein]]; NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of FN1 mRNA]]; NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of FN1 protein]]; NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of IFNG protein]]; NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of IL6 protein]]; NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of NLRP3 protein]]; NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of PDGFRB mRNA]]; NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of PDGFRB protein]]; NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFBR1 mRNA]]; NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFBR1 protein]]; NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]]; tetramethylpyrazine inhibits the reaction [Paraquat results in decreased expression of NFE2L2 protein] tetramethylpyrazine analog results in increased expression of NFE2L2 protein; tetramethylpyrazine results in increased expression of NFE2L2 mRNA; tetramethylpyrazine results in increased expression of NFE2L2 protein
tetramethylpyrazine inhibits the reaction [Methylnitrosourea results in increased expression of NFKBIA protein] NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in decreased expression of NFKBIA protein]]; tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in decreased expression of NFKBIA protein]
NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of NLRP3 protein]]; tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of NLRP3 protein]
tetramethylpyrazine results in increased expression of NOS2 mRNA tetramethylpyrazine inhibits the reaction [Oxazolone results in increased expression of NOS2 mRNA]
DDAH2 promotes the reaction [tetramethylpyrazine inhibits the reaction [Iron-Dextran Complex results in decreased phosphorylation of NOS3 protein]]; tetramethylpyrazine inhibits the reaction [Iron-Dextran Complex results in decreased phosphorylation of NOS3 protein]
tetramethylpyrazine inhibits the reaction [Hydrogen Peroxide results in increased expression of PDGFRB mRNA]; tetramethylpyrazine inhibits the reaction [Hydrogen Peroxide results in increased expression of PDGFRB protein] NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of PDGFRB mRNA]]; NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of PDGFRB protein]]; tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of PDGFRB mRNA]; tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of PDGFRB protein]
NFE2L2 affects the reaction [tetramethylpyrazine inhibits the reaction [Ethanol results in decreased expression of PPARA mRNA]]; NFE2L2 affects the reaction [tetramethylpyrazine inhibits the reaction [Ethanol results in decreased expression of PPARA protein]]; tetramethylpyrazine inhibits the reaction [Ethanol results in decreased expression of PPARA mRNA]; tetramethylpyrazine inhibits the reaction [Ethanol results in decreased expression of PPARA protein]
tetramethylpyrazine results in increased expression of PPARG protein tetramethylpyrazine results in increased expression of PPARG mRNA tetramethylpyrazine inhibits the reaction [Oxazolone results in increased expression of PPARG protein]
tetramethylpyrazine inhibits the reaction [sodium arsenite results in increased expression of PTGS2 protein] tetramethylpyrazine inhibits the reaction [Oxazolone results in increased expression of PTGS2 mRNA]
NFE2L2 affects the reaction [tetramethylpyrazine inhibits the reaction [Ethanol results in increased expression of RELA protein]]; tetramethylpyrazine inhibits the reaction [Ethanol results in increased expression of RELA protein]; tetramethylpyrazine inhibits the reaction [Oxazolone results in increased expression of RELA mRNA] tetramethylpyrazine inhibits the reaction [sodium arsenite results in increased expression of RELA protein modified form] tetramethylpyrazine promotes the reaction [Methylnitrosourea affects the localization of RELA protein]
tetramethylpyrazine inhibits the reaction [Paraquat results in increased expression of SHH mRNA]; tetramethylpyrazine inhibits the reaction [Paraquat results in increased expression of SHH protein]
tetramethylpyrazine inhibits the reaction [Paraquat results in increased expression of SMO mRNA]; tetramethylpyrazine inhibits the reaction [Paraquat results in increased expression of SMO protein]
NFE2L2 affects the reaction [tetramethylpyrazine inhibits the reaction [Ethanol results in increased expression of SREBF1 mRNA]]; NFE2L2 affects the reaction [tetramethylpyrazine inhibits the reaction [Ethanol results in increased expression of SREBF1 protein]]; tetramethylpyrazine inhibits the reaction [Ethanol results in increased expression of SREBF1 mRNA]; tetramethylpyrazine inhibits the reaction [Ethanol results in increased expression of SREBF1 protein]
NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFBR1 mRNA]]; NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFBR1 protein]]; tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFBR1 mRNA]; tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFBR1 protein]
tetramethylpyrazine inhibits the reaction [sodium arsenite results in increased expression of TNF protein] NFE2L2 affects the reaction [tetramethylpyrazine inhibits the reaction [Ethanol results in increased expression of TNF protein]]; NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]]; tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; tetramethylpyrazine inhibits the reaction [Ethanol results in increased expression of TNF protein]; tetramethylpyrazine inhibits the reaction [Oxazolone results in increased expression of TNF mRNA] tetramethylpyrazine inhibits the reaction [TNF protein promotes the reaction [Gentamicins results in increased expression of CASP8 protein]]
browse the term
